Long-Term Safety and Efficacy Study of GSK4527226 in People Aged 50 to 85 With Early Alzheimers Disease

What this Trial Is About

Researchers are evaluating the long-term safety and efficacy of the medicine GSK4527226 in people with early Alzheimers Disease, including those with mild cognitive impairment and mild dementia due to Alzheimers. This study is an open-label extension, meaning all participants will receive the same medicine. Participants must have completed the parent study called study 219867 to join this extension study. In this study, all participants will be given GSK4527226. The study will last up to 112 weeks, during which participants will receive the medicine and be monitored regularly. The open-label extension allows researchers to observe the effects of GSK4527226 over a longer period than in the original study. Participants will have regular assessments including monitoring for treatment-emergent adverse events, serious adverse events, and imaging abnormalities related to amyloid. Cognitive and functional abilities will be evaluated using several tests such as the Clinical Dementia Rating, AD Assessment Scale-Cognitive subscale, Mini-Mental State Exam, and others at multiple time points up to 104 weeks. The study includes safety monitoring and aims to gather detailed information about the medicines effects during long-term use.

Open-label Extension Study in Participants With Early Alzheimer's Disease